Lilly Buys Centessa for $7.8 Billion to Fight Sleep Disorders
Eli Lilly is acquiring Centessa in a $7.8 billion deal to develop breakthrough OX2R drugs for narcolepsy, idiopathic hypersomnia, and excessive daytime sleepiness.
XY Feed↓
/ What's going on?
Filter:
PepGen’s Low-Dose DM1 Data Falls Flat: Minimal Splicing Correction and No Clear Functional Benefit
PepGen’s latest low-dose (5 mg/kg) DM1 data shows minimal splicing correction and almost no functional improvement over placebo.
Alumis Stock Crashes in Classic “Sell the News” After Strong Phase 3 Psoriasis Data
Alumis shares plunged after strong Phase 3 psoriasis data for envudeucitinib. HC Wainwright cuts price target to $25 citing rising competition.
Lilly Signs $2.75B AI Drug Deal with Hong Kong’s Insilico Medicine
Eli Lilly has signed a $2.75 billion deal with Hong Kong-listed AI biotech Insilico Medicine for a GLP-1 diabetes drug.
Wells Fargo Calls Boston Scientific’s WATCHMAN Trial “Good, Not Great”
Wells Fargo says Boston Scientific’s CHAMPION-AF trial met all endpoints for WATCHMAN FLX but calls results “good, not great” due to slightly higher stroke rate vs blood thinners.
Morgan Stanley Boosts Insmed on Strong Brinsupri Outlook
Morgan Stanley upgrades Insmed to Overweight and raises price target to $212.
Big Move in Autoimmune Space: Aurinia to Buy Kezar Life Sciences
Aurinia Pharmaceuticals has agreed to acquire Kezar Life Sciences for $6.955 in cash per share plus a Contingent Value Right (CVR).
Game-Changer for IPF: Inhaled Tyvaso Preserves Lung Function in Major TETON-1 Study
The United Therapeutics TETON-1 trial shows that inhaled Tyvaso preserves lung function by 130 mL versus placebo and reduces disease progression. Positive results were seen across all patient groups, with an FDA filing planned for this summer.
Viridian’s Elegrobart Data: Promising Proptosis Win, But Missing the Full Picture for Thyroid Eye Disease
Viridian highlights 54% proptosis response for Elegrobart in TED, but secondary endpoints like inflammation and diplopia showed limited gains.
FDA Fast-Tracks Zymeworks’ New Ovarian Cancer Drug ZW191
Zymeworks receives U.S. FDA Fast Track Designation for ZW191, its FRα-targeting antibody-drug conjugate for advanced platinum-resistant ovarian cancer.
“Sell the News” Hits Rocket: Kresladi Approved, But Shares Fall
Rocket Pharmaceuticals won FDA approval for Kresladi and a valuable Priority Review Voucher, yet the stock dropped. Analysts explain the "sell the news" reaction, dilution concerns, and why they remain bullish with Outperform ratings.
Needham Initiates Buy Rating on BioAge Labs with $50 Price Target
Analysts are bullish on lead asset BGE-102, an oral NLRP3 inhibitor for cardiovascular risk in obese patients.
AstraZeneca Shares Jump as COPD Drug Tozorakimab Delivers Positive Results
AstraZeneca’s experimental drug tozorakimab significantly reduced COPD flare-ups in two Phase 3 trials. Promising new hope for millions of patients with chronic lung disease.
FDA Approves KRESLADI: First Gene Therapy for Rare, Life-Threatening Childhood Immune Disorder
The FDA has approved KRESLADI, Rocket Pharma’s one-time gene therapy for children with severe LAD-I — a rare, life-threatening immune disorder.
H.C. Wainwright Initiates Buy Rating on Palisade Bio with $7 Target
Analysts say PALI-2108 offers better safety and efficacy for ulcerative colitis compared to older PDE4 inhibitors.
Kodiak Sciences Stock Surges After Strong Phase 3 Eye Drug Results
Kodiak Sciences shares surged after Zenkuda hit its primary endpoint in the GLOW2 Phase 3 study for diabetic retinopathy.
WVE-007 Shows Muscle-Preserving Fat Loss in Early Data, But Weight Reduction Remains Modest
Wave Life Sciences' WVE-007 (INHBE-targeted) showed ~5% total fat reduction and 14% visceral fat drop with muscle preserved after one dose. Early results are modest (1% weight loss), but support infrequent dosing as potential GLP-1 complement.
Emergent BioSolutions Secures $60M+ in New Smallpox Defense Contracts
Emergent BioSolutions wins $54M U.S. government contract for VIGIV plus $6.6M international orders for ACAM2000 smallpox vaccine.
Why Merck’s Big CML Bet Makes Enliven’s ELVN-001 a Takeover Star
Merck’s $6.7B acquisition of Terns Pharmaceuticals highlights huge potential in CML therapies. Why analysts see Enliven’s ELVN-001 as a best-in-class winner with strong takeover appeal.
FDA Approves First Brain-Penetrating Treatment for Hunter Syndrome in Nearly 20 Years
The FDA has approved Denali’s AVLAYAH, the first brain-penetrating enzyme therapy for Hunter syndrome (MPS II) in nearly 20 years.
FDA Greenlights Relacorilant + Nab-Paclitaxel for Hard-to-Treat Ovarian Cancer
The FDA has approved Corcept's relacorilant (Lifyorli) in combination with nab-paclitaxel for platinum-resistant ovarian, fallopian tube, or peritoneal cancer, showing improved survival by several months.
BofA Calls Bicara Therapeutics a Buy – Sees Ficerafusp Alfa as Transformative
BofA starts coverage on Bicara Therapeutics with a Buy rating and $35 price target. Ficerafusp alfa shows strong potential in head and neck cancer with clear differentiation over standard care.
Sarepta Hits Early Win With New siRNA Drugs for Rare Muscle Diseases – Beating Rivals on Delivery and Safety
Sarepta just shared first test results for two new medicines aimed at rare muscle diseases FSHD1 and DM1. Early data show the drugs reach high levels in muscle safely, with no serious side effects. Shares jumped.
Why Investors Punished Maze Stock Despite Strong MZE829 Diabetes Data
Maze’s new kidney pill MZE829 cut harmful protein in urine by 35.6% in its Phase 2 trial — including patients with diabetes. Stock still fell 30% as analysts say “don’t compare it to Vertex” but remain very bullish.
Anavex Pulls Alzheimer’s Drug Application in Europe After EMA Feedback
Anavex Life Sciences has withdrawn its EU marketing application for blarcamesine as an add-on therapy for early Alzheimer’s. Shares fell sharply after EMA committee feedback.
Morgan Stanley Bullish on Immix Biopharma: Sees $1B+ Opportunity for NXC-201 CAR-T Therapy
Morgan Stanley initiated coverage on Immix Biopharma with an Overweight rating and $20 price target.
BofA Upgrades Acadia Pharmaceuticals to Buy After 25% Pullback
BofA upgrades Acadia Pharmaceuticals (ACAD) to Buy from Neutral with a $29 price target.
Merck Buys Terns Pharmaceuticals for $6.7 Billion to Boost Blood Cancer Pipeline with Promising CML Drug
Merck is buying Terns Pharmaceuticals for $6.7 billion to add TERN-701, a promising new oral drug for chronic myeloid leukemia (CML). The move strengthens its cancer pipeline as Keytruda patent expiry nears in 2028.
Grifols Plans U.S. IPO for Biopharma Business to Cut Debt and Boost Growth
Grifols has approved a U.S. IPO of a minority stake in its Biopharma business.
Clear Street: Gilead Deal Highlights Huge Potential in Cullinan’s Pipeline
Gilead’s up to $2.2B acquisition of Ouro Medicines highlights strong potential for Cullinan Therapeutics’ velinotamig. Clear Street maintains Buy rating with $33 PT.
Wall Street Goes Bullish on Sutro Biopharma: Two Major Upgrades After Q4 Results
Wells Fargo upgrades to Overweight with $27 PT and H.C. Wainwright raises to Buy with $28 target on strong STRO-004 progress.
Immunic Gets Buy Rating from Guggenheim – Dual-Action MS Pill Shows Strong Potential
Guggenheim launches coverage on Immunic at Buy with a $7 target. The dual-action MS drug vidofludimus calcium targets both inflammation and nerve protection – Phase 3 data could drive major gains.
FDA Slaps ImmunityBio with Warning Letter Over Misleading ANKTIVA Ads
ImmunityBio shares dropped 20% after the FDA issued a warning letter accusing the company of false claims that ANKTIVA cures all cancers.
Goldman Sachs Downgrades Ultragenyx to Neutral After Setrusumab Trial Miss
Goldman Sachs downgraded Ultragenyx from Buy to Neutral and slashed its price target to $25 after setrusumab Phase 3 miss in osteogenesis imperfecta. GTX-102 in Angelman syndrome now key focus, but risks remain.
Half the Patients Saw Dramatic Spleen Shrinkage: SENTRY Trial Shows Strong Results (With One Notable Miss) for New Myelofibrosis Combo
Karyopharm’s (KPTI) SENTRY trial delivers strong spleen reduction and promising survival data with selinexor + ruxolitinib — though symptom improvement was not superior. $30M cash boost extends runway into late 2026.
Gilead Acquires Ouro Medicines for $2.18 Billion to Boost Autoimmune Pipeline
Gilead to acquire Ouro Medicines for $1.675B upfront + $500M milestones, adding clinical-stage BCMAxCD3 therapy gamgertamig for severe autoimmune conditions. Partnership with Galapagos announced.
Gilead Sciences Eyes $2 Billion Deal for Autoimmune Biotech Ouro Medicines
Gilead Sciences eyes up to $2B deal for autoimmune biotech Ouro Medicines, with $1.5B upfront + milestones, amid strong stock & deal spree.
Damora Therapeutics Taps Biotech Veteran Jennifer Jarrett as President and CEO
Damora has appointed biotech leader Jennifer Jarrett as President and Chief Executive Officer, effective March 30, 2026. Two industry veterans also join the Board of Directors.
Wolfe Research Turns Bullish on Celldex, Upgrading to Outperform and Citing Stronger 2026 Catalysts
Wolfe Research upgrades Celldex Therapeutics to Outperform from Peer Perform, citing stronger 2026 catalysts and depressed valuation for rebound potential.
Pfizer and Valneva Lyme Vaccine Shows Over 70% Efficacy in Phase 3 Trial — But Misses Main Goal
Pfizer and Valneva reported their Lyme disease vaccine demonstrated 73.2% efficacy in the Phase 3 VALOR trial. While it missed the primary statistical target due to fewer cases, strong results support upcoming regulatory submissions.
Insmed’s Arikayce Scores Big Win in Phase 3 Study – Could Soon Treat Early-Stage MAC Lung Disease
Insmed announced positive topline results from the Phase 3b ENCORE study of Arikayce in newly diagnosed MAC lung disease. The drug showed statistically significant improvements in respiratory symptoms and culture conversion rates vs standard therapy.
Apogee’s Long-Acting Eczema Shot Keeps Skin Clear with Just 2 Injections a Year
Apogee Therapeutics’ Phase 2 data show zumilokibart maintains strong skin clearance and itch relief in moderate-to-severe eczema for 52 weeks with dosing every 3 or 6 months.
Solid Biosciences Gets Wall Street Boost: Guggenheim Initiates Buy, Cites Advantage Over Sarepta in DMD
Guggenheim starts SLDB coverage with Buy rating and $26 price target. SGT-003 gene therapy shows safer profile vs Sarepta's Elevidys, eyes accelerated FDA approval.
FIGS Gets a Fresh Boost: Oppenheimer Upgrades to Outperform, Sees a Sustained Recovery Ahead
Oppenheimer upgrades FIGS stock to Outperform from Perform with $22 target, citing sustained recovery, improved ops, and undervalued long-term growth in healthcare apparel.
FDA Approves First-Ever Treatment for Acquired Hypothalamic Obesity – IMCIVREE Now Available
Rhythm Pharmaceuticals receives FDA approval for IMCIVREE (setmelanotide) — the first and only treatment for acquired hypothalamic obesity.
Corcept Director Drops $3.35 Million on 100,000 Shares – Strong Insider Buy Signal
Corcept Therapeutics director Leonard Baker Jr. purchased 100,000 common shares at ~$33 each in open-market buys.
Roche Abandons Emugrobart – Clears Path for Scholar Rock’s Apitegromab to Dominate SMA
Roche halts emugrobart development, clearing path for Scholar Rock's apitegromab to dominate SMA muscle therapy market. Cantor sees multi-billion potential.
Lilly’s Retatrutide Crushes Weight Loss Goals in First Phase 3 Trial – Wall Street Says It’s a ‘Key Pillar’ for Growth
Eli Lilly’s retatrutide delivered up to 2.0% A1C reduction and 16.8% weight loss (36.6 lbs) in its first Phase 3 trial for type 2 diabetes. Analysts call it a key growth driver for Lilly with strong results vs Mounjaro.
Schizophrenia Focus Pays Off — Canaccord Starts MPLT at Buy, Sees $35 Value on ML-007 Alone
Canaccord Genuity starts coverage on MapLight Therapeutics (MPLT) with Buy rating and $35 price target.
Elliott Takes Big Stake in Invisalign Maker Align Technology to Boost Slumping Stock
Activist investor Elliott Investment Management takes major stake in Align Technology, Invisalign maker, to push for stock price gains amid post-pandemic slump.
MoonLake Immunotherapeutics Gets Bullish Upgrade: Analyst Sees $40 Target as FDA Path Clears for Sonelokimab in HS
Rothschild Redburn upgrades MoonLake to Buy from Neutral. Sonelokimab's FDA path for HS clears major hurdle; seen as best-in-class contender attractive to big pharma.
Novo Nordisk Faces More Pain: Bernstein Initiates Underperform Coverage
Bernstein initiates Underperform on Novo Nordisk, citing endless earnings downgrades, weak catalysts, U.S. price deflation, and 2032 patent cliff risks.
Ovid Stock Surges on Surprise Q4 Profit Beat and $60M PIPE to Expand OV329 into New Seizure Indications
Ovid Therapeutics shares climbed after swinging to a surprise Q4 profit beat and raising $60 million via PIPE financing. Funds will expand OV329 development into tuberous sclerosis complex and infantile spasms.
TD Cowen Turns Bullish on Grail: Upgrade to Buy After 60% Plunge Creates Bargain Entry
TD Cowen upgrades Grail to Buy from Hold with $65 target after 60% selloff. Analyst sees attractive entry in multi-cancer detection despite NHS study miss.
Arcturus Therapeutics Stands Out in mRNA Space – B. Riley Initiates Buy with $22 Price Target
B. Riley starts coverage on Arcturus Therapeutics with Buy, praising its standout lipid-enabled mRNA platform for cystic fibrosis (ARCT-032) and OTC deficiency (ARCT-810) programs.
Myriad Genetics Scores FDA Nod for MyChoice CDx – The Only Approved HRD Test Guiding Zejula Therapy
Myriad Genetics' MyChoice CDx gains FDA approval as the only CDx to identify HRD-positive patients for Zejula maintenance in advanced ovarian cancer, boosting precision therapy.
China’s NMPA Fast-Tracks Gyre Therapeutics’ Hydronidone (F351)
China’s NMPA has granted priority review to Gyre Therapeutics’ NDA for Hydronidone (F351) for chronic hepatitis B liver fibrosis.
JPMorgan Boosts Edgewise Therapeutics Target to $45: Bullish on 2026 Catalysts and EDG-7500 Momentum
JPMorgan boosts Edgewise Therapeutics price target to $45 from $34, maintains Overweight rating. Bullish on EDG-7500 catalysts and strong 2026 setup.
Aldeyra Stock Plunges as FDA Rejects Reproxalap Dry Eye Drug in Major Setback
Aldeyra Therapeutics receives FDA Complete Response Letter rejecting reproxalap for dry eye disease due to insufficient efficacy. No safety issues. ALDX shares crash.
Tenax Therapeutics: Cantor Sees 2x–3x Upside as First PH-HFpEF Drug Nears Pivotal Data
Cantor Fitzgerald initiates Overweight on Tenax Therapeutics with $35 target. Under-the-radar biotech nears Q3 2026 Phase 3 readout for potential first PH-HFpEF therapy — high-risk, high-reward setup.
LENSAR-Alcon Merger Terminated After FTC Block Threat; Stock Plunges
LENSAR and Alcon have mutually terminated their merger after the Federal Trade Commission threatened to block the deal.
Rhythm Announces EMANATE Topline Results: Primary Endpoints Missed, But Next-Gen Drugs Get a Boost
Rhythm Pharmaceuticals announced that setmelanotide missed its primary endpoints in the Phase 3 EMANATE trial. Post-hoc analyses showed statistically significant BMI reductions in POMC/PCSK1 and SRC1 patients.
Why HSBC Just Turned Bearish on Eli Lilly: Price Wars and Overhyped Weight-Loss Expectations
HSBC downgraded Eli Lilly to Reduce from Hold, cutting its price target to $850 from $1,070. The analyst cites an overhyped $150B+ obesity market, rising price competition, and expected cuts in 2026.
Tandem Diabetes Stock Gets a Boost: Analyst Upgrade Signals 50%+ Upside Potential
Piper Sandler upgrades Tandem Diabetes to Overweight from Neutral, raises PT to $33 from $21. Mobi pump, pharmacy pricing, and international growth drive revenue upside.
BioMarin Halts Voxzogo Phase 2 Trials in Turner Syndrome, SHOX Deficiency & ACAN Deficiency After SCFE Safety Events
BioMarin is discontinuing Phase 2 Voxzogo trials for Turner Syndrome, SHOX-deficiency and ACAN-deficiency after SCFE events in investigator-sponsored studies. Noonan syndrome and most ISS trials continue as planned.
Jefferies Goes All-In on Biotech: 5 Buy-Rated Stocks Poised for Big 2026 Catalysts
Jefferies initiates Buy on Design Therapeutics ($15 PT) & assumes coverage on Revolution Medicines ($140), Kymera ($110), Immatics ($18), Insmed ($228).
CytomX Shares Surge on Strong Phase 1 Data for Varsetatug Masetecan in Late-Line Colorectal Cancer
Shares of CytomX Therapeutics surged after strong Phase 1 trial data for Varsetatug Masetecan showed tumor shrinkage in late-stage colorectal cancer patients with mostly mild side effects.
Weight Watchers Beats 2025 Guidance as GLP-1 Clinical Subscribers Jump 42%
WW International reported Q4 and full-year 2025 results beating guidance, with strong growth in clinical subscribers thanks to GLP-1 integration.
Jefferies Slaps Buy Rating on Cogent Biosciences as FDA Accepts Bezuclastinib NDA for Non-Advanced Systemic Mastocytosis
Jefferies analyst started coverage on Cogent Biosciences with a Buy rating and $55 price target after the FDA accepted the NDA for bezuclastinib in Non-Advanced Systemic Mastocytosis. PDUFA date set for December 30, 2026.
Structure Therapeutics' Oral Obesity Pill Aleniglipron Hits Record 16.3% Weight Loss in Phase 2 Trial – Matches Injectables with No Plateau
Structure Therapeutics' oral pill aleniglipron achieved 15–16% body weight loss (up to 39 lbs) after 44 weeks in Phase 2, rivaling injectables with better tolerability and no plateau. Phase 3 is planned for 2026—a potential game changer for obesity treatment.
BTIG Initiates Buy on Zevra After $50M Portfolio Sale and Debt-Free Move
BTIG starts coverage on ZVRA with Buy rating and $23 target after Zevra sells SDX portfolio for $50 million and becomes debt-free.
Abivax Gets a $160 Boost: Jefferies Sees 'Differentiated' Obefazimod as UC Game-Changer
Jefferies starts Abivax coverage with Buy rating and $160 target. Views obefazimod as differentiated UC therapy; Q2 maintenance data de-risked for approval path.
ImmunityBio Builds the “World Bank of NK Cells”: 5 Billion Cancer-Fighting Cells from One Blood Draw in Just 12 Days
ImmunityBio just hit a huge milestone – they can now mass-produce and freeze powerful NK cells from healthy and cancer donors. One simple blood draw gives 8–10 ready-to-use doses.
Raymond James Upgrades Korro Bio to Outperform, Turns Bullish on Hyperammonemia Pivot
Raymond James upgrades Korro Bio to Outperform from Market Perform with $23 PT, bullish on pivot to hyperammonemia programs in UCDs & HE with strong preclinical data and high unmet need.
Immutep Halts Pivotal Lung Cancer Trial for Futility – Analysts Issue Sharp Downgrades
Immutep’s key Phase 3 trial for its cancer drug efti was stopped early due to poor results. Analysts from Citizens and Baird downgraded the stock.
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod 5 Pods
Insulet has launched a voluntary medical device correction for specific lots of Omnipod 5 Pods due to possible tubing issues. All other pods remain safe.
Natera Launches Zenith Genomics as GeneDx Plunges in Rare Disease Testing Showdown
Natera launches Zenith Genomics — its next-generation whole-genome sequencing test for faster rare disease diagnosis. GeneDx shares drop 8% as competition intensifies in the rare-disease market, which carries a $1 trillion economic burden.
Abivax Rejects Rumors of Exclusive AstraZeneca Due Diligence Until March 23
French biotech company Abivax strongly rejects media claims that it gave AstraZeneca secret access to its data for a possible buyout until March 23, calling the reports "unfounded rumors."
Oppenheimer Initiates ProQR Coverage with Outperform and $9 Target – Unmet Need in Liver Diseases Drives Optimism
Oppenheimer starts ProQR Therapeutics (PRQR) coverage with Outperform rating and $9 price target, citing RNA editing potential in liver diseases ahead of 2026 data.
AstraZeneca Leads Bid for Abivax as Eli Lilly Waits in the Wings
AstraZeneca gains exclusive data access to acquire surging French biotech Abivax (up 1,600% in 2025) before March 23 deadline; Eli Lilly waits in wings amid IBD drug promise.
Solid Biosciences Reports Strong Interim Results for SGT-003 Gene Therapy in Duchenne Trial
Solid Biosciences’ gene therapy SGT-003 shows early promise for Duchenne; trial patients improved muscle and heart function, with potential accelerated FDA approval in 2026.
Wells Fargo gives Atrium Therapeutics a Strong Buy rating on its rare cardiomyopathy programs
Wells Fargo analyst initiates coverage on Atrium Therapeutics with Overweight rating and $25 price target, highlighting big potential in RNA therapies for rare genetic heart diseases with no current treatments.
Kala Bio Stock Surges as First Biotech AI Agent Launches in Just 14 Days
Kala Bio shares surged 63% premarket to 48 cents after announcing the launch of its first purpose-built AI agent for biotech in just 14 days through the rebranded Researgency.ai platform.
Ocugen Gets Wall Street Boost: Oppenheimer Initiates Outperform Coverage with $10 Price Target
Oppenheimer starts coverage on Ocugen with an Outperform rating and $10 price target, highlighting its lead gene therapy OCU400 in Phase 3 for retinitis pigmentosa and big market potential by 2027.
C-Further Selects MiNK’s iNKT Platform for First Pediatric Oncology Partnership
MiNK Therapeutics announces a new collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, including up to $1.1 million in funding.
Albumin Slowdown in China Forces Grifols Downgrade: Morgan Stanley Moves to Equal Weight
Morgan Stanley downgraded Grifols stock to Equal Weight with a lower €11 price target, citing slowdowns in key products like albumin in China and alpha-1.
Vertex's Povetacicept Delivers Solid IgAN Data — But No Real Threat to Vera's Atacicept, Says BofA
BofA reaffirms Buy on Vera Therapeutics; Vertex’s povetacicept Phase 3 interim results in IgAN meet expectations but pose no major competitive threat.
FDA Issues Warning Letter to Novo Nordisk Over Delayed Safety Reports for Ozempic and Victoza
Novo Nordisk receives FDA warning letter after 2025 Plainsboro inspection revealed failures in timely reporting serious side effects for drugs like Ozempic and Victoza. Company says no impact on production.
FDA Lifts Rejection and Schedules August 2026 Review for Deramiocel
Capricor Therapeutics receives new PDUFA target date of August 22, 2026 for Deramiocel BLA. Potential first therapy to treat both heart and skeletal muscle damage in Duchenne muscular dystrophy (DMD).
BioNTech Co-Founders Ugur Sahin and Özlem Türeci Launch New mRNA Biotech as Company Sharpens Focus on Cancer Pipeline
BioNTech co-founders Ugur Sahin & Özlem Türeci are starting an independent next-gen mRNA company by end-2026. BioNTech keeps focus on oncology (15 Phase 3 trials).
BridgeBio Stock Gets Double Upgrade: Analysts See $93–$94 Target Ahead
JPMorgan & William Blair raise BridgeBio price targets to $93–$94 on strong Attruby launch and achondroplasia data.
Teladoc Stock Surges as Deutsche Bank Calls Shares "Compelling" and Sees Exit Upside
Deutsche Bank upgrades Teladoc Health to Buy from Hold with $11 price target, calling valuation compelling amid BetterHelp stabilization and potential exit upside.
Mineralys Shares Fall After FDA Accepts NDA for Lorundrostat – Explore-OSA Misses Primary Endpoint but Delivers Strong BP Reduction
Mineralys receives FDA acceptance of NDA for lorundrostat for hypertension. PDUFA target date: December 22, 2026. Explore-OSA missed primary endpoint but demonstrated meaningful BP reduction.
Vertex’s Povetacicept Hits Primary + All Secondary Endpoints in Phase 3 IgAN Trial
Vertex Pharmaceuticals' povetacicept succeeds in Phase 3 RAINIER trial for IgA nephropathy with 52% proteinuria reduction. Positive safety data and FDA submission planned soon.
FDA Clears Path for Haduvio, But Trevi’s “Safe” Two-Trial Plan Sends TRVI Down
Trevi Therapeutics shares plunged despite positive FDA alignment for Haduvio in IPF chronic cough. Plans for two Phase 3 trials (instead of one) triggered sell-off; Stifel holds Buy rating on the de-risked program.
Relmada Therapeutics Stock Surges After Strong NDV-01 Bladder Cancer Data and $160 Million Raise
Relmada shares jumped sharply after positive 12-month Phase 2 trial data for NDV-01 in bladder cancer and announcement of $160M financing to advance development.
H.C. Wainwright: Roche’s “Disappointing” persevERA Failure Is Not a Full Read-Through for Olema
H.C. Wainwright calls Roche’s persevERA trial disappointing but says it’s not a full readthrough for Olema Oncology. Different CDK4/6 inhibitor (ribociclib) may favor palazestrant in OPERA-02.
EZH2 Class Hit: ORIC Down After Tazverik Withdrawal
Oric Pharmaceuticals shares fell after Ipsen pulled Tazverik from all markets due to safety concerns in a key trial. Tazverik sales were already weak—a blow to confidence in similar EZH2 drugs like ORIC’s, even if they are not the same.
Buy Alert on XFOR: Guggenheim Highlights Mavorixafor as a Game-Changer in Rare Blood Disorders
Guggenheim starts coverage on X4 Pharmaceuticals with a Buy rating and $12 price target, highlighting major potential from mavorixafor in rare blood disorders like WHIM syndrome and chronic neutropenia.
Dianthus Therapeutics Scores Early Phase 3 Win in CIDP: Claseprubart Hits GO Decision Ahead of Schedule
Dianthus shares surged after an early “GO” decision in Phase 3 CAPTIVATE trial of claseprubart for CIDP. Strong 50%+ response rate and clean safety profile reported. Top-line data expected by end of 2026.